Display Settings:

Format

Send to:

Choose Destination
    Arthritis Rheum. 2009 Jun;60(6):1851-61.

    Familial Mediterranean fever with a single MEFV mutation: where is the second hit?

    Source

    Genetics and Genomics Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland 20892-1820, USA.

    Abstract

    OBJECTIVE:

    Familial Mediterranean fever (FMF) has traditionally been considered an autosomal-recessive disease; however, it has been observed that a substantial number of patients with clinical FMF possess only 1 demonstrable MEFV mutation. The purpose of this study was to perform an extensive search for a second MEFV mutation in 46 patients diagnosed clinically as having FMF and carrying only 1 high-penetrance FMF mutation.

    METHODS:

    MEFV and other candidate genes were sequenced by standard capillary electrophoresis. In 10 patients, the entire 15-kb MEFV genomic region was resequenced using hybridization-based chip technology. MEFV gene expression levels were determined by quantitative reverse transcription-polymerase chain reaction. Pyrin protein levels were examined by Western blotting.

    RESULTS:

    A second MEFV mutation was not identified in any of the patients who were screened. Haplotype analysis did not identify a common haplotype that might be associated with the transmission of a second FMF allele. Western blots did not demonstrate a significant difference in pyrin levels between patients with a single mutation and those with a double mutation; however, FMF patients of both types showed higher protein expression as compared with controls and with non-FMF patients with active inflammation. Screening of genes encoding pyrin-interacting proteins identified rare mutations in a small number of patients, suggesting the possibility of digenic inheritance.

    CONCLUSION:

    Our data underscore the existence of a significant subset of FMF patients who are carriers of only 1 MEFV mutation and demonstrate that complete MEFV sequencing is not likely to yield a second mutation. Screening for the set of the most common mutations and detection of a single mutation appears to be sufficient in the presence of clinical symptoms for the diagnosis of FMF and the initiation of a trial of colchicine.

    Comment in

    PMID:
    19479870
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2753538
    Free PMC Article

    Images from this publication.See all images (4) Free text

    Figure 1
    Figure 2
    Figure 3
    Figure 4

      Supplemental Content

      Icon for John Wiley & Sons, Inc. Icon for PubMed Central
      Write to the Help Desk